Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
CONCLUSIONS: Mutations of glycoproteins Ia, Ib, IIb and IIIa did not influence platelet aggregation in response to tirofiban in patients with unstable angina and non-ST-segment elevation myocardial infarction.
PMID: 26786608 [PubMed - as supplied by publisher] (Source: Sao Paulo Medical Journal)
Source: Sao Paulo Medical Journal - January 19, 2016 Category: Journals (General) Authors: Mansur AP, Roggerio A, Takada JY, Caribé PM, Avakian SD, Strunz CM Tags: Sao Paulo Med J Source Type: research
Eptifibatide infusion versus placebo in high risk patients with non-ST segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial.
CONCLUSION: Preoperative use of eptifibatide vs. placebo is linked to significantly reduced 12-month MACCE rate in patients with NSTE-ACS requiring urgent CABG, while it simultaneously seems not to confer a greater risk of postoperative bleeding.
PMID: 26771733 [PubMed - as supplied by publisher] (Source: The Journal of Cardiovascular Surgery)
Source: The Journal of Cardiovascular Surgery - January 16, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Wilczynski M, Wybraniec MT, Milewski K, Sanak M, Wita K, Buldak Ł, Kondys M, Buszman P, Bochenek A Tags: J Cardiovasc Surg (Torino) Source Type: research
Eptifibatide-Induced Thrombocytopenia—When Inhibitor Turns Killer
We report a rare case of life-threatening thrombocytopenia secondary to eptifibatide along with a literature review of available evidence. (Source: American Journal of Therapeutics)
Source: American Journal of Therapeutics - January 1, 2016 Category: Drugs & Pharmacology Tags: Case Reports Source Type: research
Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
Abstract
The use of inhibitors of glycoprotein IIb/IIIa (GPIIb/IIIa) has provided dramatic results in terms of the prevention of acute stent thrombosis and a reduction in major adverse coronary events in patients subjected to percutaneous coronary intervention. GPIIb/IIIa or αIIbβ3 is a member of the β3 subfamily of integrins, which also includes αVβ3. GPIIb/IIIa functions as a receptor for fibrinogen and several adhesion proteins sharing an arginine-glycine-aspartic acid (RGD) sequence. GPIIb/IIIa antagonists, through blockade of the receptor, prevent platelet aggregation. Among the three GPIIb/IIIa ...
Source: Current Drug Metabolism - December 11, 2015 Category: Drugs & Pharmacology Authors: Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, Coscioni E, Romano S, Romano MF Tags: Curr Drug Metab Source Type: research
Comparison between the Outcomes of Intracoronary and Intravenous Administration of Eptifibatide during Primary Percutaneous Coronary Intervention in Patients with Acute ST-Elevation Myocardial Infarction.
CONCLUSIONS: IC administration of eptifibatide during PPCI in patients with STEMI in comparison with IV administration of eptifibatide is associated with significantly better coronary reperfusion and improved clinical outcomes (IRCT2012090510751N1).
PMID: 26632161 [PubMed - as supplied by publisher] (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - December 5, 2015 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis
Protein disulfide isomerase (PDI) has two distinct CGHC redox-active sites; however, the contribution of these sites during different physiologic reactions, including thrombosis, is unknown. Here, we evaluated the role of PDI and redox-active sites of PDI in thrombosis by generating mice with blood cells and vessel wall cells lacking PDI (Mx1-Cre Pdifl/fl mice) and transgenic mice harboring PDI that lacks a functional C-terminal CGHC motif [PDI(ss-oo) mice]. Both mouse models showed decreased fibrin deposition and platelet accumulation in laser-induced cremaster arteriole injury, and PDI(ss-oo) mice had attenuated platelet...
Source: Journal of Clinical Investigation - November 4, 2015 Category: Biomedical Science Authors: Junsong Zhou, Yi Wu, Lu Wang, Lubica Rauova, Vincent M. Hayes, Mortimer Poncz, David W. Essex Source Type: research
Fibrin activates GPVI in human and mouse platelets
In this study, we demonstrate that GPVI is a receptor for fibrin and speculate that this contributes to development of an occlusive thrombus. We observed a marked increase in tyrosine phosphorylation, including the FcR chain and Syk, in human and mouse platelets induced by thrombin in the presence of fibrinogen and the αIIbβ3 blocker eptifibatide. This was not seen in platelets stimulated by a protease activated receptor (PAR)-4 peptide, which is unable to generate fibrin from fibrinogen. The pattern of tyrosine phosphorylation was similar to that induced by activation of GPVI. Consistent with this, thrombin did...
Source: Blood - September 24, 2015 Category: Hematology Authors: Alshehri, O. M., Hughes, C. E., Montague, S., Watson, S. K., Frampton, J., Bender, M., Watson, S. P. Tags: Thrombosis and Hemostasis Source Type: research
Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial [Clinical Sciences]
Conclusions—
These results demonstrate comparable safety of full-dose r-tPA plus eptifibatide with historical rates of sICH with r-tPA alone and support proceeding with a phase 3 trial evaluating full-dose r-tPA combined with eptifibatide to improve outcomes after AIS. (Source: Stroke)
Source: Stroke - August 24, 2015 Category: Neurology Authors: Adeoye, O., Sucharew, H., Khoury, J., Vagal, A., Schmit, P. A., Ewing, I., Levine, S. R., Demel, S., Eckerle, B., Katz, B., Kleindorfer, D., Stettler, B., Woo, D., Khatri, P., Broderick, J. P., Pancioli, A. M. Tags: Acute Cerebral Infarction, Emergency treatment of Stroke, Thrombolysis Clinical Sciences Source Type: research
Abstract 301A: A novel epithelial ovarian cancer protein, SUSD2, inhibits platelet activation and binding to tumor cells
Over 30% of ovarian cancer (OvCa) patients present with thrombocytosis (elevated plasma platelet count above 450,000 per cubic millimeter) at the time of diagnosis. These patients exhibit shorter survival times and a higher likelihood of advanced stage disease. Platelets have also been shown to enhance metastasis and promote tumor cell survival by coating tumor cells which provides immune escape and protection from chemotherapeutic agents. While previous studies have shown that platelets exhibit differential OvCa cell binding and facilitate cancer cell growth, the mechanism and molecules involved have yet to be elucidated....
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Lager, T., Thacker, M., Etrheim, C., Egland, K. A., Larson, M. K., Gubbels, J. A. A. Tags: Immunology Source Type: research
Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
Abstract
Glycoprotein (GP) IIb/IIIa inhibitors block platelet aggregation, reducing thrombotic events in acute coronary syndrome. They are most often utilized in patients who likely have an intracoronary thrombus. Tirofiban, eptifibatide, and abciximab are the three GP IIb/IIIa inhibitors approved for use in the United States. Each agent has unique pharmacological properties. They all have a rapid onset and are most often utilized in conjunction with heparin. Tirofiban, in particular, fell out of favor due to inferior dosing with its original Food and Drug Administration (FDA) approved indication, but has ...
Source: Vascular Pharmacology - July 15, 2015 Category: Drugs & Pharmacology Authors: King S, Short M, Harmon C Tags: Vascul Pharmacol Source Type: research
Eptifibatide in Post‐infarction Angina Patients who refused Intervention: Ajmer Postmyocardial Infarction Angina Eptifibatide Research (AJMER) Study: A Pilot Study
ConclusionIn patients with PIA who refused intervention, eptifibatide infusion resulted in earlier relief of angina albeit at the cost of increased non–life‐threatening bleeding. Further, this effect was achieved in significantly higher number of patients receiving eptifibatide infusion when compared to patients not receiving it. Primary composite endpoints, however, did not differ in two groups, but being a pilot study, this needs to be confirmed by larger study of adequate sample size. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - July 7, 2015 Category: Cardiology Authors: Rajendra Gokhroo, Kamal Kishor, Bhanwar Ranwa, Devendra Singh Bisht, Sajal Gupta, Avinash Anantharaj Tags: Original Research Article Source Type: research
Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future
Abstract
Coronary artery disease and acute myocardial infarction still represent the leading cause of mortality in developed countries. Therefore, great efforts have been made in the last decades to improve reperfusion strategies and adjunctive antithrombotic therapies. In fact, despite optimal epicardial recanalisation, a large proportion of patients still experience impaired reperfusion and in-stent thrombosis. The adjunctive use of glycoprotein (GP) IIb-IIIa inhibitors may certainly contribute in the reduction of such complications, especially when administered in the early phase of infarction. In fa...
Source: Drugs - July 1, 2015 Category: Drugs & Pharmacology Source Type: research
Population pharmacokinetics and safety of eptifibatide in healthy Chinese volunteers and simulations on the dose regimens approved for a Western population.
CONCLUSIONS: The PK model of eptifibatide was established and could provide PK information for further studies in the Chinese population.
PMID: 26104033 [PubMed - as supplied by publisher] (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - June 27, 2015 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research
Eptifibatide Salvage of Arterial Anastomotic Thrombosis in Lower Extremity Free Flap Reconstruction: A Case Report
J reconstr MicrosurgDOI: 10.1055/s-0035-1555011Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals:Table of contents | Full text (Source: Journal of Reconstructive Microsurgery)
Source: Journal of Reconstructive Microsurgery - June 26, 2015 Category: Surgery Authors: Drijkoningen, Tessavan Weel, VincentEberlin, Kyle R.Cetrulo, Curtis L. Tags: Letter to the Editor: Short Report Source Type: research
Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney disease.
Authors: Agrawal H, Aggarwal K, Littrell R, Velagapudi P, Turagam MK, Mittal M, Alpert MA
Abstract
Patients with advanced chronic kidney disease (CKD), including those treated with dialysis, are at high risk for the development of cardiovascular disease (CVD). CVD accounts for 45-50% of deaths among dialysis patients. Therapy of acute and chronic coronary heart disease (CHD) that is effective in the general population is frequently less effective in patients with advanced CKD. Drug therapy in such patients may require dose modification in some cases. Oral anti-platelet drugs are less effective in those wit...
Source: Current Cardiology Reviews - May 20, 2015 Category: Cardiology Tags: Curr Cardiol Rev Source Type: research
